| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Common Stock | Options Exercise | $14.9K | +550 | +19.57% | $27.00 | 3.36K | Jul 15, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $24K | +870 | +25.89% | $27.60 | 4.23K | Jul 15, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $50.8K | +1.11K | +26.12% | $46.00* | 5.34K | Jul 15, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $18.6K | +3.13K | +58.64% | $5.95 | 8.47K | Jul 15, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Sale | -$130K | -730 | -8.62% | $177.62* | 7.74K | Jul 15, 2021 | Direct | F1, F2 |
| transaction | NVAX | Common Stock | Sale | -$413K | -2.32K | -29.97% | $178.19* | 5.42K | Jul 15, 2021 | Direct | F1, F3 |
| transaction | NVAX | Common Stock | Sale | -$143K | -796 | -14.69% | $179.29* | 4.62K | Jul 15, 2021 | Direct | F1, F4 |
| transaction | NVAX | Common Stock | Sale | -$99.3K | -550 | -11.9% | $180.57* | 4.07K | Jul 15, 2021 | Direct | F1, F5 |
| transaction | NVAX | Common Stock | Sale | -$102K | -560 | -13.76% | $181.45* | 3.51K | Jul 15, 2021 | Direct | F1, F6 |
| transaction | NVAX | Common Stock | Sale | -$54.7K | -300 | -8.54% | $182.38* | 3.21K | Jul 15, 2021 | Direct | F1, F7 |
| transaction | NVAX | Common Stock | Sale | -$73.3K | -399 | -12.43% | $183.81* | 2.81K | Jul 15, 2021 | Direct | F1, F8 |
| transaction | NVAX | Common Stock | Sale | -$184 | -1 | -0.04% | $184.27* | 2.81K | Jul 15, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $28.7K | +4.82K | +171.58% | $5.95 | 7.63K | Jul 15, 2021 | Direct | F1, F9 |
| transaction | NVAX | Common Stock | Disposed to Issuer | -$28.8K | -161 | -2.11% | $179.14* | 7.47K | Jul 15, 2021 | Direct | F1, F9 |
| transaction | NVAX | Common Stock | Tax liability | -$404K | -2.25K | -30.15% | $179.14* | 5.22K | Jul 15, 2021 | Direct | F1, F9 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -550 | -100% | $0.00* | 0 | Jul 15, 2021 | Common Stock | 550 | $27.00 | Direct | F1, F10 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -870 | -21.74% | $0.00 | 3.13K | Jul 15, 2021 | Common Stock | 870 | $27.60 | Direct | F1, F11 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -1.11K | -8.49% | $0.00 | 11.9K | Jul 15, 2021 | Common Stock | 1.11K | $46.00 | Direct | F1, F12 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -3.13K | -5.27% | $0.00 | 56.3K | Jul 15, 2021 | Common Stock | 3.13K | $5.95 | Direct | F1, F13 |
| transaction | NVAX | Stock Appreciation Right | Options Exercise | $0 | -4.82K | -11.48% | $0.00 | 37.2K | Jul 15, 2021 | Common Stock | 4.82K | $5.95 | Direct | F1, F9, F14 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.9859 to $177.96, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F3 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.988 to $178.9871, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F4 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.0099 to $179.9087, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F5 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.14 to $180.9008, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F6 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.1643 to $182.0783, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F7 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.19 to $182.5638, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F8 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.1998 to $184.1349, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F9 | The reporting person received 2,409 shares of common stock upon the net exercise of 4,823 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 161 shares of common stock underlying the stock appreciation rights representing the base value and 2,253 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on July 15, 2021 of $179.14. |
| F10 | Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the November 14, 2016 grant date and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F11 | Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F12 | Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F13 | Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F14 | Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |